BPC
ITCI

Banque Pictet & Cie’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Banque Pictet & Cie’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,000
Closed -$1.08M – 624
2023
Q1 		$1.08M Sell
20,000
-9,068
-31% -$438K 0.01% 371
2022
Q4 		$1.54M Buy
29,068
+8,000
+38% +$401K 0.02% 333
2022
Q3 		$980K Buy
+21,068
New +$1.1M 0.01% 402

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Banque Pictet & Cie's ITCI Position: Q2 2023 in Review

Banque Pictet & Cie sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 20,000 shares — an estimated $1.08M sold.

Banque Pictet & Cie first reported a position in ITCI in Q3 2022 and held it in 3 quarters. The position peaked at $1.54M in Q4 2022. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Banque Pictet & Cie reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 20,000 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $1.08M.
  • Banque Pictet & Cie first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 3 quarters.
  • Banque Pictet & Cie's Intra-Cellular Therapies Inc. position peaked at $1.54M in Q4 2022.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Banque Pictet & Cie's 13F filing for Q2 2023, filed 4 Aug 2023.